Dr. Justin Killebrew brings over 15 years of research and drug discovery experience in the areas of oncology and immunology. He joined Good Therapeutics in 2018 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022. Before joining Good, he was Director of Discovery Biology at Silverback Therapeutics, where he oversaw in vitro and in vivo research in support of their lead ADC program.
Prior to Silverback, he held positions of increasing responsibility within the research organization at Bristol-Myers Squibb, where he advanced multiple therapeutic programs within the areas of Immuno-Oncology and Immunoscience. Dr. Killebrew received his Ph.D. in Immunology from the University of Washington.